Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults

@inproceedings{Waller2011DoseresponseEO,
  title={Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults},
  author={Philip A Waller and Pramod K Gopal and Gregory J Leyer and Arthur C Ouwehand and Cheryl Reifer and Morgan E Stewart and Larry E. Miller},
  booktitle={Scandinavian journal of gastroenterology},
  year={2011}
}
OBJECTIVE To assess the impact of Bifidobacterium lactis HN019 supplementation on whole gut transit time (WGTT) and frequency of functional gastrointestinal (GI) symptoms in adults. MATERIAL AND METHODS We randomized 100 subjects (mean age: 44 years; 64% female) with functional GI symptoms to consume a proprietary probiotic strain, B. lactis HN019 (Fonterra Research Centre, Palmerston North, New Zealand), at daily doses of 17.2 billion colony forming units (CFU) (high dose; n = 33), 1.8… CONTINUE READING
Highly Cited
This paper has 39 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Gut Microbes: From Bugs to Drugs

The American Journal of Gastroenterology • 2010

Probiotics and functional gastrointestinal disorders in children.

Journal of pediatric gastroenterology and nutrition • 2009
View 1 Excerpt

Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. lactis HN019 in human infants aged 0–2 years

JW Dekker, K Wickens, +3 authors P Fitzharris
Int Dairy J 2009;19:149–54 • 2009
View 1 Excerpt

Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?

Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva • 2009